|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
VANCOUVER, British Columbia, Dec. 27, 2018 -- Cryptobloc Technologies Corp., (“Cryptobloc” or the “Company”) (CSE:CRYP), (OTCMKTS:RGTZF), (Frankfurt Stock Exchange:GR9) is.
VANCOUVER, British Columbia, Dec. 12, 2018 -- Cryptobloc Technologies Corp., (“Cryptobloc” or the “Company”) (CSE:CRYP), (OTC:CRYBF), (FSE:GR9) announces that it will be.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) comments on the news release regarding the British Columbia Securities Commission (“BCSC”) Temporary Order dated November 26, 2018. The BCSC issued a temporary order on Monday, November 26, 2018, which centers around share issuances by 11 CSE issuers to a very large group of consultants between February, 2018, and August, 2018. Abattis has been named as 1 of the 11 issuers as they have ongoing consulting agreements with certain members listed in the group of respondents (the “Respondents”) for services ranging from accounting and finance to marketing. Also, certain of the Respondents participated in an Abattis private placement for $2.25M. For these reasons, Abattis has been named as an issuer in this temporary order.
At the request of the Canadian Securities Exchange (the “CSE”) and in furtherance of the Company’s effort to have its shares reinstated for trading, Cryptobloc provides the following update in respect of the imposition of a trading halt by the CSE on securities of the Company and a general corporate update. The Company’s current management team of Mr. Rob Abenante (Chief Executive Officer) and Kent McParland (Chief Financial Officer) were not involved with and had no relationship with the Company prior to their respective appointments on June 29 and July 4, 2018, and as such disclaim responsibility for any of the Company’s activities prior to those dates. The information provided in this news release has been garnered from trading information and a review of available corporate documentation but not on any personal knowledge of Messrs.